Delayed Onset Perforating Folliculitis Associated with Sorafenib

The letter to the editor discussed a case of delayed onset perforating folliculitis associated with the use of sorafenib, a medication commonly used in oncology. The authors, from various departments at Hospital Álvarez-Buylla and Hospital Universitario Central de Asturias in Spain, highlighted the dermatological side effects observed in a patient undergoing treatment with sorafenib. This case contributed to the understanding of the drug's adverse effects, emphasizing the need for awareness and monitoring of skin conditions in patients receiving sorafenib.